Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.

Background: Postoperative nausea and vomiting (PONV) are significant issues in surgical patients, and additional treatment options are needed. Dopaminergic antiemetics have been popular for their efficacy, but their use has been limited by safety concerns, especially the potential for torsade de pointes arising from QT interval prolongation. Intravenous (IV) amisulpride, a dopamine D2 and D3 antagonist shown to be effective at preventing and treating PONV at doses of 5 and 10 mg, respectively, has a dose-dependent effect on QT but at 5 mg is not associated with clinically meaningful prolongation of the heart rate-corrected QT (QTc) interval.

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers.

Purpose: Intravenous amisulpride, a dopamine D/D antagonist, has recently been shown in trials to be an effective antiemetic at low doses. This study was conducted to investigate the metabolism and elimination of a single dose of intravenous C-labeled amisulpride in healthy, adult volunteers.

Patients And Methods: Six healthy male volunteers aged 18-65 years were given a single 10 mg dose of C-labeled amisulpride containing not more than 1.

Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial.

Background: Although antiemetics are commonly used to prevent postoperative nausea or vomiting, the failure rate is appreciable and there is currently no generally accepted standard for rescue treatment of postoperative nausea or vomiting after failed prophylaxis. This prospective, randomized, double-blind, parallel-group, placebo-controlled, multicenter study was designed to test the hypothesis that intravenous amisulpride, a dopamine D2/D3-antagonist, is superior to placebo at treating established postoperative nausea or vomiting after failed prophylaxis.

Methods: A total of 2,285 adult patients undergoing surgery under general inhalational anesthesia and receiving standard antiemetic prophylaxis were enrolled at 23 sites in Canada, France, Germany, and the United States.

Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.

Purpose: The purpose of this study was to investigate the antiemetic effect of the dopamine D- and dopamine D-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy.

Methods: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.

Host-Microbe Interactions: Winning the Colonization Lottery.

Stochastic bottlenecks during bacterial colonization of animal hosts lead to reduced genetic diversity in the resulting microbiota and, at low-inoculation doses, can result in hosts that remain uncolonized. Bacterial strains vary in their colonization efficiency and resistance to displacement.

Intravenous buspirone for the prevention of postoperative nausea and vomiting.

Rationale: Buspirone, a partial 5HT(1A) agonist and D₂ and D₃ antagonist, has shown promising antiemetic efficacy when given parenterally in animal models, but its efficacy for the prevention of postoperative nausea and vomiting (PONV) is unknown.

Objective: To study the efficacy and dose-responsiveness of intravenous buspirone for the prevention of PONV.

Methods: A randomised, double-blind, placebo-controlled study was performed in adults at moderate to high PONV risk undergoing surgery with a general anaesthetic.